Who are Emalex Biosciences's investors?

Emalex Biosciences's investors include Paragon Biosciences LLC, Bain Capital Life Sciences, Fidelity Investments, Valor Equity Partners.

How much funding has Emalex Biosciences raised?

Emalex Biosciences has disclosed $250M raised across 1 round.

Emalex Biosciences

4 known investors

Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome. The company, created by Paragon Biosciences, advanced the asset through clinical development and was acquired by Teva Pharmaceutical Industries in 2026.

Biotech Medical Devices

Investors · 4

Paragon Biosciences LLC✓ verifiedChicago

Bain Capital Life SciencesBoston

Fidelity Investmentsreported · 2 sourcesBoston

Valor Equity Partnersreported · 2 sourcesChicago

Funding

SEC filings, press & company announcements

$250M disclosed across 1 round · 2022

$250MSeries DNov 2022 · 4 sources
Bain Capital Life Sciences (lead), Fidelity Management & Research Company, Paragon Biosciences, Valor Equity Partners
Source ↗
Undisclosed amountSeries CMar 2021
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Emalex Biosciences Raises $250M in Series D Financing Roundfinsmes.com · Nov 2022

Emalex wants to fill gaps in 'exceptionally difficult' Tourette syndrome with massive $250M raisefiercebiotech.com · Nov 2022

Emalex Closes $250M Series D to Fund Phase III Trial in Tourette Syndrome - BioSpacebiospace.com · Nov 2022

Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndromeprnewswire.com · Nov 2022

Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trialsparagonbiosci.com · Mar 2021

Frequently asked questions

What does Emalex Biosciences do?: Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome. The company, created by Paragon Biosciences, advanced the asset through clinical development and was acquired by Teva Pharmaceutical Industries in 2026.
Who are Emalex Biosciences's investors?: Emalex Biosciences's investors include Paragon Biosciences LLC, Bain Capital Life Sciences, Fidelity Investments, Valor Equity Partners.
How much funding has Emalex Biosciences raised?: Emalex Biosciences has disclosed $250M raised across 1 round.